CELL INTELLIGENCE · 肿瘤细胞治疗研究

阻断 CD19 CAR-T 细胞上的 CD30 增强其抗 B 细胞白血病/淋巴瘤的功能能力

Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma.

CD20 逃逸的双重触发模型：儿童 B-ALL 中转录本过载诱导的 NONO 调控与隐秘剪接

Dual-trigger model of CD20 escape: NONO regulation and cryptic splicing induced by transcript overload in pediatric B-ALL.

这些发现与一个模型一致，即 NONO 表达和 MS4A1 的转录水平动态与儿童 B-ALL 中的 CD20 异质性相关。这些观察可能有助于理解儿童 B-ALL 中 CD20 表达和抗原可用性的变异性。

整合以维奈克拉为基础的靶向和/或免疫治疗用于慢性淋巴细胞白血病

Integrating venetoclax-based targeted and/or immune therapies for chronic lymphocytic leukemia.

同步自体移植与 CD19 CAR-T 细胞二线治疗序贯 CD20 × CD3 双特异性抗体治疗难治性伯基特淋巴瘤：病例报告

Simultaneous auto-transplant and CD19 CAR T-cell 2nd line therapy followed by CD20 × CD3 bispecific antibody for refractory Burkitt lymphoma, a case r

慢性淋巴细胞白血病中的感染：不断演变的风险与预防策略

Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies.

靶向药物时代慢性淋巴细胞白血病新型疗法的开发

The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs.

tafasitamab 在滤泡性淋巴瘤中日益凸显的作用

The emerging role of tafasitamab in follicular lymphoma.

评估完全缓解/缓解率作为复发/难治性慢性淋巴细胞白血病的替代终点

Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia.

CD40L 与 IL-4 通过 HLA-E:NKG2A 轴抑制 NK 细胞介导的抗体依赖性细胞毒性

CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis.

这些结果揭示了 B 细胞恶性肿瘤中抗 CD20 治疗耐药的新机制，并表明抗 NKG2A 联合抗 CD20 可改善 CLL 或 NHL 患者的治疗。

靶向 LILRB1 的 CAR-T 细胞用于血液系统恶性肿瘤治疗

LILRB1-directed CAR-T cells for the treatment of hematological malignancies.